savolitinib savolitinib savolitinib is an experimental small molecule inhibitor of c-met. it is being investigated for the treatment of cancer by astrazeneca. it is in phase ii clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. it has been given conditional approval for these indication in china. savolitinibclinical dataother namesvolitinibidentifiers iupac name 3-pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolopyrazine cas number1313725-88-0chemspider34501055unii2a2da6857rkeggd11139echa infocard100.238.920 chemical and physical dataformulac17h15n9molar mass345.370 g·mol−13d model (jsmol)interactive image smiles c(c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(c)c3)nc21 inchi inchi=1s/c17h15n9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11h,1-2h3/t11-/m0/s1key:xydnmozjkogzls-nshdsacasa-n